{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["107(12)"],"submitter":["Hofland J"],"pubmed_abstract":["The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide termed \"theranostics.\" Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well-differentiated (neuro-)endocrine neoplasms (NENs). PRRT with 177Lu-DOTATATE was approved by the regulatory authorities in 2017 and 2018 for selected patients with low-grade well-differentiated gastroenteropancreat"],"journal":["The Journal of clinical endocrinology and metabolism"],"pagination":["3199-3208"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9693835"],"repository":["biostudies-literature"],"pubmed_title":["Peptide Receptor Radionuclide Therapy."],"pmcid":["PMC9693835"],"pubmed_authors":["Verburg FA","Feelders RA","de Herder WW","Hofland J","Brabander T"],"additional_accession":[]},"is_claimable":false,"name":"Peptide Receptor Radionuclide Therapy.","description":"The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide termed \"theranostics.\" Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well-differentiated (neuro-)endocrine neoplasms (NENs). PRRT with 177Lu-DOTATATE was approved by the regulatory authorities in 2017 and 2018 for selected patients with low-grade well-differentiated gastroenteropancreat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T22:46:21.397Z","creation":"2025-04-19T22:46:21.397Z"},"accession":"S-EPMC9693835","cross_references":{"pubmed":["36198028"],"doi":["10.1210/clinem/dgac574"]}}